Highlights Galapagos NV

Equities

GLPG

BE0003818359

Market Closed - Euronext Amsterdam Other stock markets 11:35:09 2024-05-07 am EDT			Pre-market 01:51:02 am
27.24 ^EUR	+1.11%		27.09	-0.55%

May. 03	Transcript : Galapagos NV, Q1 2024 Earnings Call, May 03, 2024
May. 02	Galapagos NV Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Galapagos NV Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Galapagos Showcases Innovative Approach in Hematological Cancer Care with Clinical and Translational Data Presentations at EBMT Congress 2024	Apr. 08	CI
Galapagos to Seek Acquisitions	Feb. 23	CI
Galapagos NV Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 21	CI
Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024	Feb. 15	CI
Galapagos Completes Sale of Jyseleca Business to Alfasigma	Feb. 01	MT
Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV.	Jan. 30	CI
Galapagos NV Enters into Strategic Collaboration Agreement with Thermo Fisher Scientific, Inc. to Further Expand Its Decentralized CAR-T Manufacturing Network in the U.S	Jan. 05	CI
Galapagos Partners with Thermo Fisher for Manufacturing in US	Jan. 05	MT
Galapagos, Thermo Fisher Scientific to Establish Decentralized CAR-T Manufacturing Network	Jan. 04	MT
Galapagos, BridGene Biosciences Partner to Develop New Medicines for Oncology Targets	Jan. 04	MT
Galapagos to Collaborate With BridGene to Discover, Develop New Medicines for Oncology Targets	Jan. 03	MT
BridGene Biosciences, Inc. Announces Strategic Collaboration and Licensing Agreement with Galapagos NV	Jan. 03	CI
Global markets live: HSBC, Baidu, Exxon Mobil, Geely, Tesla...	Jan. 02
Galapagos to Divest Jyseleca Business in Biotechnology Shift	Jan. 02	MT
Galapagos Announces Start of PAPILIO-1 Phase 1/2 Multiple Myeloma Study of Point-Of-Care Manufactured BCMA CAR-T Candidate, GLPG5301	Dec. 21	CI
Galapagos Presents New Encouraging Clinical Data from the Ongoing Phase 1/2 CD19 CAR-T Studies with GLPG5201 and GLPG5101	Dec. 12	CI
Galapagos Signs Strategic Manufacturing Deal With Landmark Bio	Nov. 06	MT
Galapagos Nv Releases New Encouraging Data from Car-T Studies for Presentation At Ash 2023	Nov. 03	CI
Galapagos NV Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Galapagos NV

Equities

GLPG

BE0003818359

Highlights

Filters